Literature DB >> 26509509

Glaucoma Blindness at a Tertiary Eye Care Center.

Jordan S Stone1, Kelly W Muir2, Sandra S Stinnett3, Jullia A Rosdahl4.   

Abstract

BACKGROUND: Glaucoma is an important cause of irreversible blindness. This study describes the characteristics of a large, diverse group of glaucoma patients and evaluates associations between demographic and clinical characteristics and blindness.
METHODS: Data were gathered via retrospective chart review of patients (N = 1,454) who were seen between July 2007 and July 2010 by glaucoma service providers at Duke Eye Center. Visual acuity and visual field criteria were used to determine whether patients met the criteria for legal blindness. Descriptive and comparative statistical analyses were performed on the glaucoma patients who were not blind (n = 1,258) and those who were blind (n = 196). A subgroup analysis of only those patients with primary open-angle glaucoma was also performed.
RESULTS: In this tertiary care population, 13% (n = 196) of glaucoma patients met criteria for legal blindness, nearly one-half of whom (n = 94) were blind from glaucoma, and another one-third of whom (n = 69) had glaucoma-related blindness. The most common glaucoma diagnosis at all levels of vision was primary open-angle glaucoma. A larger proportion of black patients compared with white patients demonstrated vision loss; the odds ratio (OR) for blindness was 2.25 (95% CI, 1.6-3.2) for black patients compared with white patients. The use of systemic antihypertensive medications was higher among patients who were blind compared with patients who were not blind (OR = 2.1; 95% CI, 1.4-3.1). A subgroup analysis including only patients with primary open-angle glaucoma showed similar results for both black race and use of systemic antihypertensive medications. The relationship between use of systemic antihypertensive medications and blindness was not different between black patients and white patients (interaction P = .268). LIMITATIONS: Data were based on chart review, and associations may be confounded by unmeasured factors.
CONCLUSIONS: Treated systemic hypertension may be correlated with blindness, and the cause cannot be explained solely by race. In addition, this study demonstrated that there is continued disparity between black patients and white patients with regards to blindness from glaucoma. ©2015 by the North Carolina Institute of Medicine and The Duke Endowment. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 26509509      PMCID: PMC4792093          DOI: 10.18043/ncm.76.4.211

Source DB:  PubMed          Journal:  N C Med J        ISSN: 0029-2559


  21 in total

Review 1.  Vascular risk factors in glaucoma: a review.

Authors:  Masahide Yanagi; Ryo Kawasaki; Jie Jin Wang; Tien Y Wong; Jonathan Crowston; Yoshiaki Kiuchi
Journal:  Clin Exp Ophthalmol       Date:  2011-04       Impact factor: 4.207

2.  [Intraocular pressure and prevalence of occult glaucoma in a village of Murcia].

Authors: 
Journal:  Arch Soc Esp Oftalmol       Date:  2000-03

3.  Epidemiology of glaucoma: what's new?

Authors:  Colin Cook; Paul Foster
Journal:  Can J Ophthalmol       Date:  2012-06       Impact factor: 1.882

4.  Relationship between ocular perfusion pressure and retrobulbar blood flow in patients with glaucoma with progressive damage.

Authors:  D Gherghel; S Orgül; K Gugleta; M Gekkieva; J Flammer
Journal:  Am J Ophthalmol       Date:  2000-11       Impact factor: 5.258

5.  Why do some people go blind from glaucoma?

Authors:  W M Grant; J F Burke
Journal:  Ophthalmology       Date:  1982-09       Impact factor: 12.079

6.  Estimating the rate of progressive visual field damage in those with open-angle glaucoma, from cross-sectional data.

Authors:  Aimee Teo Broman; Harry A Quigley; Sheila K West; Joanne Katz; Beatriz Munoz; Karen Bandeen-Roche; James M Tielsch; David S Friedman; Jonathan Crowston; Hugh R Taylor; Rohit Varma; M Cristina Leske; Boel Bengtsson; Anders Heijl; Mingguang He; Paul J Foster
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-01       Impact factor: 4.799

7.  The Framingham Eye Study. II. Association of ophthalmic pathology with single variables previously measured in the Framingham Heart Study.

Authors:  H A Kahn; H M Leibowitz; J P Ganley; M M Kini; T Colton; R S Nickerson; T R Dawber
Journal:  Am J Epidemiol       Date:  1977-07       Impact factor: 4.897

8.  Risk factors for incident open-angle glaucoma: the Barbados Eye Studies.

Authors:  M Cristina Leske; Suh-Yuh Wu; Anselm Hennis; Robert Honkanen; Barbara Nemesure
Journal:  Ophthalmology       Date:  2007-07-16       Impact factor: 12.079

Review 9.  Risk and risk factors for blindness from glaucoma.

Authors:  Philip P Chen
Journal:  Curr Opin Ophthalmol       Date:  2004-04       Impact factor: 3.761

10.  Risk factors for progression to blindness in high tension primary open angle glaucoma: Comparison of blind and nonblind subjects.

Authors:  Karanjit S Kooner; Mohannad AlBdoor; Byung J Cho; Beverley Adams-Huet
Journal:  Clin Ophthalmol       Date:  2008-12
View more
  4 in total

1.  Large Disparities in Receipt of Glaucoma Care between Enrollees in Medicaid and Those with Commercial Health Insurance.

Authors:  Angela R Elam; Chris Andrews; David C Musch; Paul P Lee; Joshua D Stein
Journal:  Ophthalmology       Date:  2017-06-02       Impact factor: 12.079

2.  Enhancement of pharmacokinetic and pharmacological behavior of ocular dorzolamide after factorial optimization of self-assembled nanostructures.

Authors:  Enas A M R Afify; Ibrahim Elsayed; Mary K Gad; Magdy I Mohamed; Abd El-Moneim M R Afify
Journal:  PLoS One       Date:  2018-02-05       Impact factor: 3.240

3.  Identifying risk factors for blindness from primary open-angle glaucoma by race: a case-control study.

Authors:  Andrew M Williams; Wei Huang; Kelly W Muir; Sandra S Stinnett; Jordan S Stone; Jullia A Rosdahl
Journal:  Clin Ophthalmol       Date:  2018-02-20

4.  Etiological spectrum of irreversible blindness in Kashmir in North India.

Authors:  Madhurima Kaushik; Shah Nawaz; Haniyaa Mufti; Tariq Syed Qureshi
Journal:  Indian J Ophthalmol       Date:  2021-10       Impact factor: 1.848

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.